文献速递肝胆胰外科围术期管理与 ERAS

胰腺导管腺癌切除术后复发模式、时机与预测因素

Patterns, Timing, and Predictors of Recurrence Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma.
PubMed 文献 · Ann Surg · 2018-01-01

该研究基于约翰霍普金斯医院2000至2010年692例胰腺导管腺癌切除患者,中位随访25.3个月,76.7%复发,中位无复发生存期11.7个月。孤立远处复发占57.8%,孤立局部复发占23.7%;肝转移出现早(中位6.9月),肺转移出现晚(中位18.6月)。淋巴结阳性比率>0.2是全远处复发的强预测因素,辅助化疗或放化疗可减少复发并延长无复发生存期。

要点

  • 胰腺癌切除术后76.7%患者复发,中位无复发生存期11.7个月。
  • 肝转移出现早(中位6.9月),肺转移出现晚(中位18.6月)。
  • 淋巴结阳性比率>0.2是全远处复发的强预测因素。

核心结论

  • 不同复发部位具有不同预测因素和无复发生存曲线,支持肿瘤存在独特生物学差异导致不同复发模式的假说。

研究设计与样本

  • 回顾性队列研究,纳入约翰霍普金斯医院2000至2010年接受胰腺切除术的胰腺导管腺癌患者,排除随访记录不完整、随访<24个月及接受新辅助治疗者,最终692例有详细随访数据。

主要发现

  • 中位随访25.3个月,531例(76.7%)复发,中位无复发生存期11.7个月。
  • 孤立远处复发307例(57.8%),孤立局部复发126例(23.7%)。
  • 单纯肝复发134例(25.2%),中位复发时间6.9个月;单纯肺复发78例(14.7%),中位复发时间18.6个月。
  • 淋巴结阳性比率>0.2是全远处复发的强预测因素。
  • 接受辅助化疗或放化疗者复发更少,中位无复发生存期分别为18.0个月和17.2个月。

临床怎么用

  • 术后随访应根据不同复发模式的时间分布进行个体化安排,肝转移需早期监测。
  • 淋巴结阳性比率>0.2提示远处复发风险高,可考虑更密切随访。
  • 辅助化疗或放化疗与更少复发和更长无复发生存期相关。

局限性

  • 单中心回顾性研究,排除随访不完整、随访<24个月及新辅助治疗患者,可能影响结果外推。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To describe accurately the pattern, timing, and predictors of disease recurrence after a potentially curative resection for pancreatic ductal adenocarcinoma (PDAC). SUMMARY BACKGROUND DATA: After surgery for PDAC, most patients will develop disease recurrence. Understanding the patterns and timing of disease failure can help guide improvements in therapy. METHODS: Patients who underwent pancreatectomy for PDAC at the Johns Hopkins Hospital between 2000 and 2010 were included. Exclusion criteria were incomplete follow-up records, follow-up <24 months, and neoadjuvant therapy. The first recurrence site was recorded and recurrence-free survival (RFS) was estimated using Kaplan-Meier curves. Predictive factors for specific recurrence patterns were assessed by univariate and multivariate analyses using Cox-proportional hazard regression models. RESULTS: From the identified cohort of 1103 patients, 692 patients had comprehensive and detailed follow-up data available. At a median follow-up of 25.3 months, 531 (76.7%) of the 692 had recurred after a median RFS of 11.7 months. Most patients recurred at isolated distant sites (n = 307, 57.8%), while isolated local recurrence was seen in 126 patients (23.7%). Liver-only recurrence (n = 134, 25.2%) tended to occur early (median 6.9 mo), while lung-only recurrence (n = 78, 14.7%) occurred later (median 18.6 mo). A positive lymph node ratio >0.2 was a strong predictor for all distant disease recurrence. Patients receiving adjuvant chemotherapy or chemoradiotherapy had fewer recurrences and a longer RFS of 18.0 and 17.2 months, respectively. CONCLUSIONS: Specific recurrence locations have different predictive factors and possess distinct RFS curves, supporting the hypothesis that unique biological differences exist among tumors leading to distinct patterns of recurrence.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Groot VP, Rezaee N, Wu W, et al. Patterns, Timing, and Predictors of Recurrence Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma. Ann Surg. 2018. PMID: 28338509. doi:10.1097/SLA.0000000000002234

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。